Dyadic International (DYAI) Current Deferred Revenue (2018 - 2026)
Dyadic International (DYAI) posted Current Deferred Revenue of $1.1 million for Q1 2026, down 35.84% sequentially from $1.7 million in Q4 2025, and up 66.95% YoY from $665216.0 in Q1 2025.
Dyadic International (DYAI) Current Deferred Revenue (2018 - 2026) Analysis & Trends
Dyadic International has reported Current Deferred Revenue for 9 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 66.95% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 66.95% YoY) and the FY2025 annual result came in at $1.7 million, up 107.58% from the prior year.
- Current Deferred Revenue fell to $1.1 million in Q1 2026 per DYAI's latest filing, from $1.7 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $315.0 million in Q1 2022 and troughed at $9000.0 in Q2 2023.
- A 5-year average of $19.2 million and a median of $534018.0 in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue jumped 37300.62% in 2022, then tumbled 99.98% in 2023.
- Over 5 years, Current Deferred Revenue stood at $40743.0 in 2022, then jumped by 1102.94% to $490113.0 in 2023, then jumped by 70.13% to $833813.0 in 2024, then soared by 107.58% to $1.7 million in 2025, then tumbled by 35.84% to $1.1 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.1 million, $1.7 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.11 Mn |
| Dec 31, 2025 | 1.73 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 665,216.00 |
| Dec 31, 2024 | 833,813.00 |
| Sep 30, 2024 | 514,483.00 |
| Jun 30, 2024 | 482,323.00 |
| Mar 31, 2024 | 534,018.00 |
| Dec 31, 2023 | 490,113.00 |
| Sep 30, 2023 | 13,897.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | 65,207.00 |
| Dec 31, 2022 | 40,743.00 |
| Sep 30, 2022 | 445,044.00 |
| Jun 30, 2022 | 901,331.00 |
| Mar 31, 2022 | 315.01 Mn |
| Dec 31, 2021 | 151,147.00 |
| Sep 30, 2021 | 162,680.00 |
| Jun 30, 2021 | 258,748.00 |